Literature DB >> 15522279

Angiotensin AT2 receptor contributes to cardiovascular remodelling of aged rats during chronic AT1 receptor blockade.

Emma S Jones1, M Jane Black, Robert E Widdop.   

Abstract

Ang II acting at AT(1)Rs has well documented effects on cardiovascular structure such as the promotion of cardiovascular hypertrophy and fibrosis, effects which are believed to be opposed by AT(2)R stimulation. AT(1) and AT(2)R expression are up regulated in senescent hearts, and other components of the local renin-angiotensin system are also dramatically increased in the ageing heart. Therefore, the aim of this study was to determine the role of the AT(2)R in aged rats by determining their potential contribution to the chronic antihypertensive and cardiovascular effects of AT(1)R blockade. Radiotelemetry probes were implanted into senescent (20 months) male Wistar-Kyoto (WKY) rats, and baseline recordings of mean arterial pressure (MAP) were made for 1 week. Candesartan cilexetil (2 mg/kg per day) was given in drinking water, while an additional group simultaneously received the AT(2)R antagonist, PD123319 (10 mg/kg per day) via osmotic mini-pump. At the end of the 4 weeks treatment period, animals were perfusion-fixed to enable histological analysis of cardiovascular structure. MAP was decreased by candesartan cilexetil, however, this effect was not further influenced by PD123319. Cardiac hypertrophy and fibrosis, and aortic hypertrophy were all significantly reduced by candesartan cilexetil. Most interestingly, these structural changes were reversed by concomitant PD123319 administration, despite the lack of AT(2)R-mediated effects on MAP. These results suggest that the AT(2)R does not exert a significant influence on chronic blood pressure regulation in senescent rats. However, PD123319 did reverse AT(1)R-mediated regression of cardiovascular hypertrophy and fibrosis, highlighting the important role of the AT(2)R on cardiovascular structure in the ageing heart and vasculature.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15522279     DOI: 10.1016/j.yjmcc.2004.08.004

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  21 in total

Review 1.  Transforming growth factor beta signaling in adult cardiovascular diseases and repair.

Authors:  Thomas Doetschman; Joey V Barnett; Raymond B Runyan; Todd D Camenisch; Ronald L Heimark; Henk L Granzier; Simon J Conway; Mohamad Azhar
Journal:  Cell Tissue Res       Date:  2011-09-28       Impact factor: 5.249

2.  Immune-inflammatory dysregulation modulates the incidence of progressive fibrosis and diastolic stiffness in the aging heart.

Authors:  Katarzyna A Cieslik; George E Taffet; Signe Carlson; Jesus Hermosillo; Joann Trial; Mark L Entman
Journal:  J Mol Cell Cardiol       Date:  2010-10-23       Impact factor: 5.000

3.  The angiotensin II type 2 receptor agonist Compound 21 is protective in experimental diabetes-associated atherosclerosis.

Authors:  Bryna S M Chow; Christine Koulis; Pooja Krishnaswamy; Ulrike M Steckelings; Thomas Unger; Mark E Cooper; Karin A Jandeleit-Dahm; Terri J Allen
Journal:  Diabetologia       Date:  2016-05-11       Impact factor: 10.122

4.  Postmenopausal hypertension: role of the Renin-Angiotensin system.

Authors:  Licy L Yanes; Damian G Romero; Radu Iliescu; Huimin Zhang; Deborah Davis; Jane F Reckelhoff
Journal:  Hypertension       Date:  2010-08-02       Impact factor: 10.190

Review 5.  Mitral valve disease in Marfan syndrome and related disorders.

Authors:  Daniel P Judge; Rosanne Rouf; Jennifer Habashi; Harry C Dietz
Journal:  J Cardiovasc Transl Res       Date:  2011-08-25       Impact factor: 4.132

6.  Age-dependent differential crosstalk between alpha(1)-adrenergic and angiotensin receptors.

Authors:  Yan-fang Li; Shu-tian Shi
Journal:  Can J Cardiol       Date:  2009-08       Impact factor: 5.223

7.  Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome.

Authors:  Jennifer P Habashi; Daniel P Judge; Tammy M Holm; Ronald D Cohn; Bart L Loeys; Timothy K Cooper; Loretha Myers; Erin C Klein; Guosheng Liu; Carla Calvi; Megan Podowski; Enid R Neptune; Marc K Halushka; Djahida Bedja; Kathleen Gabrielson; Daniel B Rifkin; Luca Carta; Francesco Ramirez; David L Huso; Harry C Dietz
Journal:  Science       Date:  2006-04-07       Impact factor: 47.728

Review 8.  Angiotensin II type-2 receptor-specific effects on the cardiovascular system.

Authors:  Ying Li; Xiao-Hui Li; Hong Yuan
Journal:  Cardiovasc Diagn Ther       Date:  2012-03

9.  Protective role of AT(2) and B(1) receptors in kinin B(2)-receptor-knockout mice with myocardial infarction.

Authors:  Jiang Xu; Oscar A Carretero; Liping Zhu; Edward G Shesely; Nour-Eddine Rhaleb; Xiangguo Dai; Luchen Wang; James J Yang; Xiao-Ping Yang
Journal:  Clin Sci (Lond)       Date:  2013-01       Impact factor: 6.124

10.  Angiotensin type 2 receptor actions contribute to angiotensin type 1 receptor blocker effects on kidney fibrosis.

Authors:  Takashi Naito; Li-Jun Ma; Haichun Yang; Yiqin Zuo; Yiwei Tang; Jee Young Han; Valentina Kon; Agnes B Fogo
Journal:  Am J Physiol Renal Physiol       Date:  2009-12-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.